PMID- 28433516
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20181202
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 19
IP  - 6
DP  - 2017 Jun
TI  - Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: 
      Lessons from the acute graft versus host disease experience.
PG  - 655-667
LID - S1465-3249(17)30430-9 [pii]
LID - 10.1016/j.jcyt.2017.03.006 [doi]
AB  - Bone marrow-derived mesenchymal stromal cells (BMSCs) are primitive, supportive 
      cells of the bone marrow with tri-lineage potential to differentiate into bone, 
      cartilage, fat and muscle. These cells possess both in vitro and in vivo 
      immunomodulatory and wound-healing properties. Several studies have demonstrated 
      efficacy of intravenously administered BMSCs in treating acute graft-versus-host 
      disease (GvHD). Use of intravenous (IV) BMSCs in inflammatory bowel diseases 
      (IBD) in humans has been limited to small studies in adults, but results have 
      been promising. There remain many unanswered questions regarding safety, 
      tolerability, effectiveness and optimal use of BMSCs to treat IBD, particularly 
      in immunocompromised patients. This article reviews the evidence for using BMSCs 
      to treat acute GvHD and how this experience may inform the potential use of BMSCs 
      as a treatment for IBD.
CI  - Copyright (c) 2017 International Society for Cellular Therapy. All rights reserved.
FAU - Conklin, Laurie S
AU  - Conklin LS
AD  - Division of Gastroenterology, Hepatology, and Nutrition, Children's National 
      Health System, Washington, District of Columbia, USA. Electronic address: 
      lconklin@childrensnational.org.
FAU - Hanley, Patrick J
AU  - Hanley PJ
AD  - Division of Cancer and Immunology Research, Program for Cell Enhancement and 
      Technologies for Immunotherapy, Children's National Health System, Washington, 
      District of Columbia, USA.
FAU - Galipeau, Jacques
AU  - Galipeau J
AD  - Assistant Dean for Therapeutics Discovery and Development, University of 
      Wisconsin-Madison, Madison, Wisconsin, USA.
FAU - Barrett, John
AU  - Barrett J
AD  - Stem Cell Allogeneic Transplant Section, National Institutes of Health, Bethesda, 
      Maryland, USA.
FAU - Bollard, Cather M
AU  - Bollard CM
AD  - Division of Cancer and Immunology Research, Program for Cell Enhancement and 
      Technologies for Immunotherapy, Children's National Health System, Washington, 
      District of Columbia, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170419
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
SB  - IM
MH  - Bone Marrow Cells/cytology
MH  - Graft vs Host Disease/etiology/*therapy
MH  - Humans
MH  - Inflammatory Bowel Diseases/*therapy
MH  - Injections, Intravenous
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Mesenchymal Stem Cells/physiology
OTO - NOTNLM
OT  - graft-versus-host disease
OT  - inflammatory bowel disease
OT  - mesenchymal stromal cell
EDAT- 2017/04/24 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/04/24 06:00
PHST- 2016/11/20 00:00 [received]
PHST- 2017/02/01 00:00 [revised]
PHST- 2017/03/06 00:00 [accepted]
PHST- 2017/04/24 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/04/24 06:00 [entrez]
AID - S1465-3249(17)30430-9 [pii]
AID - 10.1016/j.jcyt.2017.03.006 [doi]
PST - ppublish
SO  - Cytotherapy. 2017 Jun;19(6):655-667. doi: 10.1016/j.jcyt.2017.03.006. Epub 2017 
      Apr 19.